Eric Bell Email & Phone Number

Cambridge, MA, US

• Developed the tactical and operational plan for in vivo pharmacology and translational efforts of Rectify's hepatobiliary programs
• Generated and characterized two mouse models of hepatobiliary disease and used them to deliver in vivo PoC for first-in-class ABCB11/B4 dual PFM
• Developed translational plans for core pipeline programs and programs that are external opportunities
• Identified and facilitated outreach to KOLs for scientific feedback and HCP perspective for hepatobiliary diseases, ectopic calcification disorders, rare ophthalmology diseases, and rare CNS/PNS diseases.
• Collaborated with colleagues to develop the ABC transporter knowledgebase culminating in a Trends in Molecular Medicine publication

Cambridge, MA, US

Watertown, Massachusetts, US

• Responsible for translational science efforts in rare benign hematology
• Leading translational science for etavopivat clinical development team and contributing to the scientific strategy for life cycle management
• Developed in vivo pharmacology and translational strategy for rare benign hematology discovery programs
• Delivered data package for a no-go decision on a discovery program saving multi-million-dollar investment on an IDD contract
• Influenced scientific objectives of clinical exploratory endpoints through development and execution of an advisory board meeting

• Drove the execution of research strategy developed as a consultant utilizing one internal direct report and external resources to reach a GO decision in polycystic kidney disease
• Identified in vivo PKD models, initiated a breeding program for a genetic model at a CRO, and nominated small molecules based on in vitro activity, ADME, safety, and PK properties for in vivo evaluation
• Developed integrated timelines for in vitro and in vivo activities with overall company timelines and corporate goals, presented work to upper management and involved in presenting to investors
• Demonstrated translatability from in vitro to in vivo models of target engagement markers/biomarkers

• Identified and developed a research strategy in peripheral indications to evaluate and validate a novel protein chaperone target
• Established and executed in vitro strategy to identify target engagement markers and suitable biomarkers for pre-clinical translational work

HotSpot Therapeutics: Advise on CRO selection and oversee work, review data and experimental designMitobridge: Preparation and writing of biomarker IND report Modulus: Due diligence and competitive intelligence of oncology target, with an emphasis on pharmacology, differentiation from related targets, and enabling assaysBantam Pharmaceutical: Interrogated.

• Program Co-Lead responsible for concept, target validation, assay development and in vivo proof of concept studies of a small molecule program targeting Bach1 in sickle cell disease
• Completed several key pharmacology studies and IND reports (cellular pharmacology, in vivo pharmacology, and biomarker) for PPARδ program (MA-0211 for Duchenne Muscular Dystrophy and Mitochondrial Myopathy)
• Engaged and recruited key opinion leaders in sickle cell disease, mitochondrial myopathy, and fatty acid oxidation for advisory board and preclinical strategy
• Managed assay development, pharmacodynamic experiments, PK/PD correlation, and in vivo proof of concept experiments at CROs and with academic collaborators
• Lead the design and execution of GO/NO GO study implicating mitochondrial function in Chronic Fatigue Syndrome
• Identified an indication expansion opportunity for a lead compound by implicating mitochondria modulation from metabolomics data set on patient plasma samples

Cambridge, MA, US

• Research Scientist (8/2013-8/2014)Postdoctoral Fellow (8/2007-7/2013)Investigated the molecular genetics of aging and diseases of aging, with a focus on Sirtuins. Utilized both tissue culture systems and genetically.
• Work resulted in fourteen peer-reviewed publications and one patent
• Discovered SirT3 is a viable therapeutic strategy in cancer and diseases driven by hypoxia-inducible factor, and developed a mouse model to show feasibility.
• Major collaboration resulted in the discovery of reductive glutamine metabolism and its therapeutic potential in oncology
• Identified a major role for SirT1 in male germ cell differentiation, and as a therapeutic target for male contraception
• Supervised, trained and mentored four students and a visiting professor

• Investigated cellular oxygen sensing and biological outcomes to hypoxia.
• Acquired 2 fellowships and 1 travel award, published 11 manuscripts in peer-reviewed journals.
• Successfully Identified mitochondria as the cellular oxygen sensor.
• Identified that HIF is necessary for the hypoxic extension of replicative lifespan and sufficient for normoxic extension of replicative lifespan.

• Responsible for basic lab management.
• Published 2 manuscripts.
• Investigated the resident proteins of cardiac caveolae.

US

Validated and performed metabolite extraction from biological samples.Prepared standards and extracted metabolites for LC-MS/MS.

Doctor Of Philosophy (Phd), Cell And Molecular Biology, Cancer Biology

Bachelor Of Science (B.S.), Biology, Biotechnology